SCHEMBL3605908

SCHEMBL3605908

CON(C)C(=O)c1ccc2cnn(C3CCCC3)c2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 1/20 0.44
HTR1B P28222 1/20 0.44
HTR1F P30939 1/20 0.44
KDM2B Q8NHM5 5/20 0.39
CDK4 P11802 1/20 0.39
CCND1 P24385 1/20 0.39
CCNE1 P24864 1/20 0.39
CDK2 P24941 1/20 0.39
CCND3 P30281 1/20 0.39
CDK6 Q00534 1/20 0.39
BRD4 O60885 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
LMNA P02545 2/20 0.37
HCAR3 P49019 2/20 0.37
PDE9A O76083 2/20 0.37
PTGER3 P43115 1/20 0.36
TP53 P04637 1/20 0.36
MAPT P10636 1/20 0.36
ALDH1A1 P00352 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31191317 0.86 RXRA (0.46) HTR1AHTR1BHTR1FSMN1; SMN2LMNA
SCHEMBL7971124 0.84 ALDH1A1 (0.50) HTR1AHTR1BHTR1FCDK4CCND1
SCHEMBL7419168 0.80 HCAR3 (0.56) HTR1AHTR1BHTR1FHCAR3PDE9A
SCHEMBL30040346 0.79 HTR1A (0.50) HTR1AHTR1BHTR1FSMN1; SMN2LMNA
SCHEMBL3605904 0.78 HTR1A (0.46) HTR1AHTR1BHTR1FBRD4SMN1; SMN2
SCHEMBL989522 0.75 L3MBTL1 (0.41) KDM2BCDK4CCND1CCNE1CDK2
SCHEMBL30040860 0.74 HCAR3 (0.54) HTR1AHTR1BHTR1FHCAR3PTGER3
SCHEMBL23467071 0.74 ALDH1A1 (0.50) HTR1AHTR1BHTR1FCDK4CCND1
SCHEMBL24338759 0.74 HTR1A (0.46) HTR1AHTR1BHTR1FALDH1A1HPGD
SCHEMBL5836096 0.72 HPD (0.52) BRD4SMN1; SMN2ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7723348-B2 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORPORATION (US) 2010-05-25 US disclosed
US-7432266-B2 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORPORATION (US) 2008-10-07 US disclosed
US-20080207660-A1 PHOSPHODIESTERASE 4 INHIBITORS HOPPER ALLEN 2008-08-28 US disclosed
WO-2007123953-A2 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2007-11-01 WO disclosed
US-20070254913-A1 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORPORATION 2007-11-01 US disclosed
EP-1799673-A1 PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS Memory Pharmaceuticals Corporation (US) 2007-06-27 EP disclosed
US-20060154960-A1 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORPORATION 2006-07-13 US disclosed
WO-2006044528-A1 PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2006-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254913-A1 Phosphodiesterase 4 inhibitors PDE4A, PDE4B, PDE12 HTR1A 1094/4885HTR1B 703/4885HTR1F 543/4885
US-20080207660-A1 PHOSPHODIESTERASE 4 INHIBITORS PDE4A, PDE4B, PDE12 HTR1A 1094/4885HTR1B 703/4885HTR1F 543/4885
US-20060154960-A1 Phosphodiesterase 4 inhibitors PDE4A, PDE4B, PDE12 HTR1A 1094/4885HTR1B 703/4885HTR1F 543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.